ABOS
Acumen Pharmaceuticals, Inc.- Healthcare
- Biotechnology
- $143M market cap
Forecast run · Oct 29, 2026Upside rank 979 of 3,186
Model Signal
ForecastQ Daily Probabilities
35.1%
69.9%
34.0%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$1.98
Price target$7.00
Implied move+253.5%
Analysts8
ForecastQ Portfolios
ABOS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.